Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Apr;65(4):597–600. doi: 10.1038/bjc.1992.121

An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer.

D J Cruickshank 1, J Paul 1, C R Lewis 1, E J McAllister 1, S B Kaye 1
PMCID: PMC1977546  PMID: 1562469

Abstract

CA-125 levels were assessed prior to each of the first three cycles of chemotherapy, in 81 patients with epithelial ovarian cancer receiving first-line chemotherapy. All patients have at least 1 year's follow-up. Thirty-nine patients (48%) have progressed clinically or have died within 1 year of treatment (treatment 'failures'). Three CA-125 indices previously shown to be of prognostic value are assessed for their ability to pick-out these 'failures'. When the indices examined are modified to obtain a specificity for picking out failures just exceeding 90%, the maximum sensitivity obtained was 46%. The use of CA-125 for clinical decision making in ovarian cancer requires further investigation to determine and validate a prognostic index with acceptable sensitivity and specificity, and to determine the clinical impact of treatment decisions made using such an index.

Full text

PDF
597

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvarez R. D., To A., Boots L. R., Shingleton H. M., Hatch K. D., Hubbard J., Soong S. J., Potter M. E. CA125 as a serum marker for poor prognosis in ovarian malignancies. Gynecol Oncol. 1987 Mar;26(3):284–289. doi: 10.1016/0090-8258(87)90019-9. [DOI] [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  4. Canney P. A., Moore M., Wilkinson P. M., James R. D. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 1984 Dec;50(6):765–769. doi: 10.1038/bjc.1984.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cruickshank D. J., Fullerton W. T., Klopper A. The clinical significance of pre-operative serum CA 125 in ovarian cancer. Br J Obstet Gynaecol. 1987 Jul;94(7):692–695. doi: 10.1111/j.1471-0528.1987.tb03177.x. [DOI] [PubMed] [Google Scholar]
  6. Hawkins R. E., Roberts K., Wiltshaw E., Mundy J., Fryatt I. J., McCready V. R. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol. 1989 Dec;96(12):1395–1399. doi: 10.1111/j.1471-0528.1989.tb06301.x. [DOI] [PubMed] [Google Scholar]
  7. Heintz A. P., Van Oosterom A. T., Trimbos J. B., Schaberg A., Van der Velde E. A., Nooy M. The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. Gynecol Oncol. 1988 Jul;30(3):347–358. doi: 10.1016/0090-8258(88)90249-1. [DOI] [PubMed] [Google Scholar]
  8. Lavin P. T., Knapp R. C., Malkasian G., Whitney C. W., Berek J. C., Bast R. C., Jr CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol. 1987 Feb;69(2):223–227. [PubMed] [Google Scholar]
  9. Malkasian G. D., Jr, Melton L. J., 3rd, O'Brien P. C., Greene M. H. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol. 1984 Jun 1;149(3):274–284. doi: 10.1016/0002-9378(84)90227-8. [DOI] [PubMed] [Google Scholar]
  10. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Willemse P. H., Heintz A. P., van Lent M., Trimbos J. B., Bouma J., Vermorken J. B. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol. 1987 Aug;5(8):1157–1168. doi: 10.1200/JCO.1987.5.8.1157. [DOI] [PubMed] [Google Scholar]
  11. Parker D., Patel K., Alred E. J., Harnden-Mayor P., Naylor B. CA 125 and survival in ovarian cancer: preliminary communication. J R Soc Med. 1988 Jan;81(1):22–22. doi: 10.1177/014107688808100110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Raju R. N., Dalbow M. H., Pugh R. P., Concannon J. P., Zidar B. L., Zamerilla C. F., Schenken L. L. Clinical relevance of the CA-125 assay for the management of patients with ovarian carcinoma. Prog Clin Biol Res. 1987;248:289–297. [PubMed] [Google Scholar]
  13. Redman C. W., Blackledge G. R., Kelly K., Powell J., Buxton E. J., Luesley D. M. Early serum CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer. 1990;26(5):593–596. doi: 10.1016/0277-5379(90)90085-8. [DOI] [PubMed] [Google Scholar]
  14. Rustin G. J., Gennings J. N., Nelstrop A. E., Covarrubias H., Lambert H. E., Bagshawe K. D. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol. 1989 Nov;7(11):1667–1671. doi: 10.1200/JCO.1989.7.11.1667. [DOI] [PubMed] [Google Scholar]
  15. Vergote I. B., Børmer O. P., Abeler V. M. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol. 1987 Jul;157(1):88–92. doi: 10.1016/s0002-9378(87)80352-6. [DOI] [PubMed] [Google Scholar]
  16. Voest E. E., van Houwelingen J. C., Neijt J. P. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives. Eur J Cancer Clin Oncol. 1989 Apr;25(4):711–720. doi: 10.1016/0277-5379(89)90208-3. [DOI] [PubMed] [Google Scholar]
  17. Wiltshaw E. Ovarian trials at the Royal Marsden. Cancer Treat Rev. 1985 Sep;12 (Suppl A):67–71. doi: 10.1016/0305-7372(85)90020-9. [DOI] [PubMed] [Google Scholar]
  18. van der Burg M. E., Lammes F. B., van Putten W. L., Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol. 1988 Jul;30(3):307–312. doi: 10.1016/0090-8258(88)90244-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES